این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
The Archives of Bone and Joint Surgery، جلد ۱۱، شماره ۱۲، صفحات ۷۳۱-۷۳۷
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Screening for Femoral Head Osteonecrosis Following COVID-19: Is It Worth It?
چکیده انگلیسی مقاله Objectives: Based on WHO data, as of June 2022, there were 532.2 million confirmed COVID-19 cases globally.In the initial phase of the COVID -19 pandemic, patients experiencing critical illness marked by severe respiratorydistress were commonly subjected to corticosteroid treatment. Regrettably, the administration of exogenouscorticosteroids stands as the prevailing cause of ONFH. In the current narrative review, we aim to evaluate if activescreening should be utilized to diagnose post-COVID-19 ONFH in its early stages.Methods: The databases for PubMed, CINAHL, and Science Direct were systematically queried in March 2022.The search terms were as follows: “COVID-19”, “severe acute respiratory syndrome”, “coronavirus”, “systemicsteroid”, “corticosteroid”, “femoral head osteonecrosis”, “avascular necrosis”, or “steroid therapy.” The includedstudies for review were all required to be peer-reviewed studies in the English language with Reported complicationslinked to steroid therapy in COVID-19 patients or potential connections to the development of ONFH in individualsrecovering from the novel coronavirus have been documented.Results: Systemic corticosteroids were frequently employed in managing critically ill COVID-19 patients. The CDCreports up to June 2022 showed more than 4.8 million COVID-19 hospitalizations in the US, with approximately overone million patients receiving steroids. In a study of ONFH after infection with COVID-19, all patients had bilateralinvolvement. The average duration from the initiation of corticosteroid treatment to the onset of symptoms was 132.8days.Conclusion: In summary, a distinct correlation exists between the administration of steroids to individuals with COVID19 and the subsequent risk of ONFH. Moreover, an elevated dosage and prolonged duration of steroid therapy inCOVID-19 patients are associated with an increased likelihood of developing ONFH. Therefore, active screening forhigh-risk patients, that may have received systemic corticosteroid treatment during a COVID-19 illness, may bereasonable. Level of evidence: IV
کلیدواژه‌های انگلیسی مقاله COVID-19, Osteonecrosis of femoral head, steroid
نویسندگان مقاله | Hamid Dolat Abadi
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran


| Ali Parsa
1 Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran 2 American Hip Institute, Chicago, Illinois, USA


| John Stelzer
UConn Health, Department of Orthopedic Surgery; Farmington, Connecticut, USA


| Adam Anz
Andrews Institute for Orthopedics and Sports Medicine; Gulf Breeze, FL, USA


| M. H. Ebrahimzadeh
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran


| Farshid Bagheri
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran


| Amirshahriar Ariamanesh
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran


| Neda Mirzaei
Orthopedic Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
نشانی اینترنتی https://abjs.mums.ac.ir/article_23420.html
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده SYSTEMATIC REVIEW
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات